The advent of biological therapies targeting specific pro-inflammatory cytokines (tumor necrosis factor (TNF), interleukin (IL)-6, and IL-1), which are responsible for JIA’s pathogenesis, revolutionized the use of biological agents in the treatment of the disease [5]. Here, IL6 is linked to juvenile idiopathic arthritis.